Cordis Announces CE Mark for MYNX CONTROL Vascular Closure Device
DUBLIN, Ohio, August 22, 2019— Cordis, a Cardinal Health company, announced that it has received CE Mark approval for its MYNX CONTROL™ Vascular Closure Device (VCD). Vascular closure devices are proven to reduce time to hemostasis and ambulation in patients who have undergone diagnostic or interventional vascular procedures.1
“As we celebrate 60 years of improving patient care, Cordis continues to bring innovations to our customers that integrate their feedback and better serve their needs,” said Patrick Holt, president, Cordis. “MYNX CONTROL™ VCD reinforces Cordis’ leadership in vascular closure, providing greater ease of use to continue to expand access to the benefits of extravascular closure.”
Launched in the United States in November of 2018, MYNX CONTROL™ VCD integrates active extravascular sealing and full resorbability into a new delivery system that maximizes predictability, safety and ease of use in closing 5-7F femoral arterial access sites.
MYNX CONTROL™ VCD features a novel deployment system that enables more predictable deployment and ease of use. Highlights of the system include the automation of multiple procedure steps within the handle mechanism, a tension indicator that provides visual confirmation of device position for proper sealant deployment, and a new ergonomic handle design. MYNX CONTROL™ VCD is available in 5F as well as 6/7F sizes.
Lastly, feedback from U.S. physicians who’ve had an opportunity to use the device in their practices have been very positive and they are reporting good clinical outcomes.1-6
About Cardinal Health
Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company enhances supply chain efficiency for clinically proven medical products, pharmaceuticals and cost-effective solutions. To combat prescription drug misuse, the Cardinal Health Foundation and its education partners created Generation Rx, a national drug prevention education and awareness program. The Foundation actively supports an array of other solutions, including efforts to reduce opioid prescribing, promote drug take back and safe disposal and expand collaborative community work. Cardinal Health is backed by nearly 100 years of experience with operations in nearly 46 countries. For more information, visit cardinalhealth.com. Follow us on Twitter, Facebook andLinkedIn.
1. MYNX Control Vascular Closure Device Instructions for Use.
2. Pruski MJ Jr, Blachut AM, Konkolewska M, et al. MynxGrip for closure of antegrade puncture after peripheral interventions with same-day discharge. Vasc Endovasc Surg. 2017 Feb;51(2):67-71.
3. Baker NC, Escarcega RO, Lipinski MJ, et al. Active versus passive anchoring vascular closure devices following percutaneous coronary intervention: a safety and efficacy comparative analysis. J Interv Cardiol. 2016 Feb; 29(1): 108-112.
4. Hutchings D, Hayat A, Karunakaran A, Malik N. Success, safety, and efficacy of the Mynx femoral closure device in a real-world cohort: single-center experience. J Invasive Cardiol. 2016 Mar;28(3): 104-108.
5. Noor S, Meyers S, Curl R. Successful reduction of surgeries secondary to arterial access site complications: a retrospective review at a single center with an extravascular closure device. Vasc Endovascular Surg. 2010 Jul;44(5):345-349.
6. Fargen KM, Hoh BL, Mocco J. A prospective randomized single-blind trial of patient comfort following vessel closure: extravascular synthetic sealant closure provides less pain than a self-tightening suture vascular compression device. J NeuroInterv Surg. 2011 Sep; 3(3): 219-223.
